Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 13:3:294.
doi: 10.3389/fmicb.2012.00294. eCollection 2012.

New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges

Anna Vecchiarelli  1 , Eva Pericolini, Elena Gabrielli, Donatella Pietrella
Affiliations

New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges

Anna Vecchiarelli et al. Front Microbiol. .

Abstract

The commensal fungus Candida albicans causes mucosal candidiasis in the rapidly expanding number of immunocompromised patients. Mucosal candidiasis includes oropharyngeal, esophageal, gastrointestinal, and vaginal infections. Vulvovaginal candidiasis (VVC) and antimycotic-refractory recurrent VVC is a frequent problem in healthy childbearing women. Both these mucosal infections can affect the quality of life and finding new therapeutical and preventive approaches is a challenge. A vaccine against candidal infections would be a new important tool to prevent and/or cure mucosal candidiasis and would be of benefit to many patients. Several Candida antigens have been proposed as vaccine candidates including cell wall components and virulence factors. Here we discuss the recent progress and problems associated with vaccination against mucosal candidiasis.

Keywords: C. albicans; candidiasis; fungal infections; mucosal candidiasis; vaccine.

PubMed Disclaimer

References

    1. Ashman R. B., Vijayan D., Wells C. A. (2011). IL-12 and related cytokines: function and regulatory implications in Candida albicans infection. Clin. Dev. Immunol. 2011, 686597.10.1155/2011/686597 - DOI - PMC - PubMed
    1. Backhed F., Hornef M. (2003). Toll-like receptor 4-mediated signaling by epithelial surfaces: necessity or threat? Microbes Infect. 5, 951–95910.1016/S1286-4579(03)00207-7 - DOI - PubMed
    1. Baquir B., Lin L., Ibrahim A. S., Fu Y., Avanesian V., Tu A., Edwards J., Jr., Spellberg B. (2010). Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J. Infect. Dis. 201, 473–47710.1086/649901 - DOI - PMC - PubMed
    1. Bar E., Gladiator A., Bastidas S., Roschitzki B., Acha-Orbea H., Oxenius A., Leibundgut-Landmann S. (2012). A novel Th cell epitope of Candida albicans mediates protection from fungal infection. J. Immunol. 188, 5636–564310.4049/jimmunol.1200594 - DOI - PubMed
    1. Bozza S., Montagnoli C., Gaziano R., Rossi G., Nkwanyuo G., Bellocchio S., Romani L. (2004). Dendritic cell-based vaccination against opportunistic fungi. Vaccine 22, 857–86410.1016/j.vaccine.2003.11.031 - DOI - PubMed

LinkOut - more resources